Average customer rating:
|
Modeling Financial Markets : Using Visual Basic.NET and Databases to Create Pricing, Trading, and Risk Management Models
Benjamin Van Vliet , and Robert Hendry Manufacturer: McGraw-Hill ProductGroup: Book Binding: Hardcover Similar Items:
ASIN: 0071417729 |
Book Description
Limitations in today's software packages for financial modeling system development can threaten the viability of any system--not to mention the firm using that system. Modeling Financial Markets is the first book to take financial professionals beyond those limitations to introduce safer, more sophisticated modeling methods. It contains dozens of techniques for financial modeling in code that minimize or avoid current software deficiencies, and addresses the crucial crossover stage in which prototypes are converted to fully coded models.
Customer Reviews:
Don't Judge a Book by Its Cover.......2006-03-10
Hands On Programming.......2006-03-06
A very misleading title.......2005-10-19
How to Program book - not Financial Modeling.......2005-07-22
Programming for Financial Types.......2005-04-14
Average customer rating: |
When Public Sector Workers Unionize (National Bureau of Economic Research Project Report)
Manufacturer: University Of Chicago Press ProductGroup: Book Binding: Hardcover ASIN: 0226261662 |
Book Description
Average customer rating: |
When Public Sector Workers Unionize
Richard B. Freeman Richard B. Freemna Manufacturer: University Of Chicago Press ProductGroup: Book Binding: Paperback ASIN: B000OP2P5Y |
Average customer rating: |
Flashes of wit from bench and bar
William C Sprague Manufacturer: Collector Pub. Co ProductGroup: Book Binding: Unknown Binding ASIN: B00087DLKQ |
Average customer rating: |
Interactions of Soil Minerals With Natural Organics and Microbes (S S S a Special Publication)
Manufacturer: Soil Science Society of Amer ProductGroup: Book Binding: Paperback ASIN: 0891187782 |
Average customer rating: |
Statins: The HMG CoA Reductase Inhibitors in Perspective
Manufacturer: Informa Healthcare ProductGroup: Book Binding: Hardcover ASIN: 1841842923 |
Book Description
Building upon the foundation set in the first edition, Statins: The HMG-CoA Reductase Inhibitors in Perspective examines existing and emerging statins and their beneficial effectiveness in reducing serum cholesterol. The breadth of coverage and depth of information in this book provide an authoritative guide to statins from their discovery through the major clinical trials to the present and explores the future of statin trials and lipid-lowering therapy beyond statins. The book tells the story of statins, for the most part in the words of those who lived it. The major clinical trials from Scandinavia, North America, Australia, New Zealand, and Scotland are detailed by those who conducted them.
Average customer rating: |
The anti-inflammatory actions of HMG-CoA reductase inhibitors in Alzheimer's disease : (Dissertation)
Andrew Christopher Cordle Manufacturer: ProQuest Information and Learning ProductGroup: Book Binding: Digital ASIN: B000F6HM6O Release Date: 2006-03-28 |
Book Description
Citation Details
Average customer rating: |
Effects of HMG-COA Reductase Inhibitor Therapy on LDL Cholesterol Blood Levels in Hyperlipidemia: A Longitudinal Retrospective Anlaysis Using a Department of Defense Integrated Database
Manufacturer: Storming Media ProductGroup: Book Binding: Spiral-bound ASIN: 1423561678 |
Product Description
This is a AIR FORCE INST OF TECH WRIGHT-PATTERSONAFB OH report procured by the Pentagon and made available for public release. It has been reproduced in the best form available to the Pentagon. It is not spiral-bound, but rather assembled with Velobinding in a soft, white linen cover. The Storming Media report number is A040543. The abstract provided by the Pentagon follows: Annual lipid-lowering therapy costs the Department of Defense (DOD) in excess of $40 million. In 1995, a new computer system was implemented nationwide to assist in tracking medical utilization in addition to performing general operations. Pharmacy, laboratory, and patient administration records were integrated. The purpose of this study was to investigate the five currently marketed HMG-CoA reductase inhibitors (statins) in the military beneficiary population served by this computer system in a selected area. The computer records of patients receiving statin therapy between February 1996 and April 1998 were retrospectively examined: (1) to determine if statin therapy achieved reductions in low-density lipoprotein (LDL) cholesterol levels similar to those seen in clinical trials; (2) to determine if there were any differences between the five statins in the LDL reductions observed; and (3) to compare the cost- effectiveness of the five statins by using annual estimated treatment costs per one percent reduction in LDL. The perspective for the cost-effectiveness analyses was that of the military. An original sample of 4436 patients resulted in 289 final subjects meeting the criteria of being new statin users and having at least one pre- treatment and post-treatment LDL value on file. As the majority of patients received one particular statin, few comparisons could be conducted. Observed reductions in LDL for patients taking pravastatin were less than predicted by clinical trials, but with 95 percent confidence intervals, approached the predicted values.
Average customer rating: |
The expanding role of the HMG-CoA reductase inhibitor, the most widely prescribed drug in the world.(CARDIOLOGY CASEBOOK) : An article from: American Journal of Critical Care
Laurie G. Futterman , and Louis Lemberg Manufacturer: Thomson Gale ProductGroup: Book Binding: Digital ASIN: B000DZVCDG Release Date: 2005-12-20 |
Average customer rating:
|
HMG-CoA Reductase Inhibitors (Milestones in Drug Therapy)
Manufacturer: Birkhauser ProductGroup: Book Binding: Hardcover ASIN: 376436307X |
Book Description
HMG-CoA reductase inhibitors (statins) are established drugs for the treatment of hypercholesterolemia. Furthermore, they induce regression of vascular atherosclerosis as well as reduction of cardiovascular-related morbidity and death in patients with and without coronary artery disease. This book deals with statins which have substantially altered the approach to therapy of atherosclerosis and its sequelae. Emphasis is placed on the scientific background to the discoveries and the development of the therapy, including an overview of the current state of knowledge of the drugs. Clinical data are reviewed extensively. This book not only provides the reader with valuable information but also stimulates further research into the pathogenesis of atherosclerosis and the mechanisms behind the action of effective statins. It sets the stage for creative thinking among scientists of many disciplines for the accomplishment of our ultimate goals in treating atherosclerosis and its sequelae. This topical volume...Customer Reviews:
Misleading Expertise.......2003-10-07
The book consists of 8 chapters by nominally highly qualified authors in the form of review articles of the sort
normally found in medical journals. These are devoted to the pharmacology and supposed benefits of statin drugs.
The writing is in expert medical language and is consistent, well-written, well-edited and very well-referenced, in
quantity if not in quality. The index is inadequate.
All chapters attempt to justify the wide use of the statin drugs to lower TC and LDL by citing references in support
of the claims that high levels have been correlated with cardiovascular disease (pp1,19,35,81,84,99,121,126). Such
claims are unfounded (Ravnskov U, The Cholesterol Myths, Washington, DC, New Trends, 2000).
The supposed benefits of the statins, beyond a large, but meaningless lowering of TC and LDL, are usually given
as lowered relative risks (RR) of mostly non-fatal heart attacks without the slightest indication of the magnitude of the
more meaningful reduction of absolute risk (pp101,103,106,115,122,124,137). This misrepresentation has been
noted (Ravnskov, 2000; Gigerenzer G, Calculated Risks: How to Know When Numbers Deceive You, New York,
NY, Simon & Schuster, 2002). So the usual tout of pravastatin in the WOSCOPS trial of a 22% drop in all-cause
mortality was noted without the information that this was only an 0.9% drop absolute in the 5-year trial period
(p106). The higher all-cause death rates in 2 of the big trials were ignored, as was the higher breast cancer rate (RR
= 1500%) in the CARE trial (Ravnskov, 2000).
Besides cancer, the other side effects of statins listed were incomplete, and should have included myalgia,
myopathy, polyneuropathy, liver and kidney damage, congestive heart failure and amnesia. Side-effects were said to
affect 2% of patients (p115-6) and 2-6% (p123). In fact, a recent review noted side-effects in 20% of patients above
the placebo rate, and no change whatever in the all-cause death rate for atorvastatin (Newman CB, Palmer G,
Silbershatz H, Szarek M. Safety of Atorvastatin Derived from Analysis of 44 Completed Trials in 9,416 Patients.
Am J Cardiol 2003;92:670-6).
Statins decrease the body's production of the essential coenzyme Q-10 and dolichol, among other things. This
was not mentioned as a problem in any chapter. While this was shown in one biochemical diagram (p65), it was not
in another (p82). Low Q-10 levels are strongly associated with congestive heart failure.
"Statins are contra-indicated during pregnancy and breastfeeding. The reason for this is that cholesterol is an
essential component for fetal development, including the synthesis of steroids and cell membranes" (p116). The
authors seem unable to comprehend that cell membranes, steroids and coenzyme Q-10 are needed by all humans.
The rare familial hypercholesterolemia, in which TC > 400 mg/dL, was represented as more deadly than it really
is (p99,111), (Ravnskov, 2000).
There was some recognition that statins operate to lower non-fatal heart attack rates by mechanisms other than
cholesterol lowering, but not that their desirable effect on thromboxane A2 is less than men can obtain with buffered
aspirin (p71), or that the desirable effect of raising nitric oxide (NO) levels is less than one can obtain with the
supplement L-arginine with no side-effects. There was no understanding that these effects of statins are independent
of initial or final TC or LDL levels (Nielsen JV. Serun lipid lowering and risk reduction? Where is the connection?
Br Med J Rapid Response, 19 Nov 01, to Kmietowicz Z. Statins are the new aspirin, Oxford researchers say. Br
Med J 2001;323:1145), and thus there is no way to determine who should be treated, or what the dose should be.
An entire chapter is devoted to the cost-benefits of statin use (p138ff). Since the use of statins for primary
prevention of CVD has been shown to increase all-cause mortality by 1% over a 10-year period (Jackson PR, et al.
Statins for primary prevention: at what coronary risk is safety assured? Br J Pharmacology 2001;52:439-446), and statins
have very little effect in secondary prevention, it would seem that there is no cost-benefit (Kauffman JM, "Do
Hypolipidemic Drugs Lower Medical Expenses?" Pharmacotherapy 2001;22(12),1583-1586).
This book may be of use for a pharmacologist looking for an overview, however narrow in outlook, with literature citations.
---Joel M. Kauffman, 6 Oct 03
Average customer rating: |
[alpha]-Asarone inhibits HMG-CoA reductase, lowers serum LDL-cholesterol levels and reduces biliary CSI in hypercholesterolemic rats.(cholesterol saturation ... Journal of Phytotherapy & Phytopharmacology
L. Rodriguez-Paez , M. Juarez-Sanchez , J. Antunez-Solis , I. Baeza , and C. Wong Manufacturer: Urban & Fischer Verlag ProductGroup: Book Binding: Digital ASIN: B0008DYP3C Release Date: 2005-07-31 |
Book Description
This digital document is an article from Phytomedicine: International Journal of Phytotherapy & Phytopharmacology, published by Urban & Fischer Verlag on June 1, 2003. The length of the article is 4957 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Average customer rating: |
The expanding role of HMG-CoA reductase inhibitors (statins) in the prevention and treatment of ischemic heart disease (Current problems in cardiology)
Robert J Chilton Manufacturer: Mosby ProductGroup: Book Binding: Unknown Binding ASIN: B0006RV2CC |
Average customer rating: |
Hmg Coa Reductase Inhibitors: New Horizons in the Management of Hypercholesterolemia - Journal: Cardiology, 1990, Suppl. 4 (Hmg Coa Reductase Inhibitors)
Manufacturer: S. Karger AG (Switzerland) ProductGroup: Book Binding: Paperback ASIN: 3805552785 |
Average customer rating: |
Review of HMG-CoA reductase inhibitors (AAFP home study self-assessment)
Kyle Callicott Manufacturer: American Academy of Family Physicians ProductGroup: Book Binding: Unknown Binding ASIN: B0006QRBPU |
Average customer rating: |
Oceanic Hotspots: Intraplate Submarine Magmatism and Tectonism
Manufacturer: Springer ProductGroup: Book Binding: Hardcover ASIN: 3540408592 |
Book Description
Ocean Hotspots provides a comprehensive overview of recent and ongoing research on intraplate volcanism in the ocean basins with special emphasis on the Pacific Ocean. The geology of the seamounts and their associated seamount chains is described, along with detailed geophysical, geochemical and hydrothermal observations made by a multi-disciplinary group of marine geoscientists. These observations lead to a deeper understanding of how the ascending mantle melts, represented by hotspots, are able to penetrate the lithosphere, build seamounts, and enhance hydrothermal circulation. The "fixed" hotspot-generated seamount chains also provide key constraints on plate tectonic reconstructions on the Earth's crust.
Average customer rating: |
Applications of Neutron Scattering to Soft Condensed Matter
Manufacturer: CRC ProductGroup: Book Binding: Hardcover ASIN: 9056993003 |
Book Description
Neutrons, which are a penetrating yet non destructive probe, are ideally suited to studying the structure, organisation and motion of molecules responsible for the physical properties of materials under a variety of conditions. Applications are in fields as diverse as colloid and polymer science, earth sciences, pharmaceutics, biology and engineering. This book will be of interest to both present and potential future users of neutron sources working in these areas, as both a useful reference and a comprehensive overview.
Average customer rating:
|
I Have Heard The Mermaids Singing
Christopher Bollas Manufacturer: Free Association Books ProductGroup: Book Binding: Hardcover Similar Items:
ASIN: 185343759X |
Customer Reviews:
Inspiring, funny, and disquietng.......2005-09-26
Psychoanalysis from the inside out.......2005-09-14
Playful meeting with psychoanalytic thinking!.......2005-09-12
Bollas' Song Must Be Heard.......2005-09-11
Average customer rating: |
The Magazine of Fantasy and Science Fiction, June 1990: Hyena Eyes; Sylwann's Choice; Final Tomte; Scoring; I Have Heard the Mermaids Singing; Down the Hatch; A Double; Designated Hitter; Science: The Salt Producers
Ray Aldridge; Roger Robert Lovin; Judith Moffett; Vance Aandahl; Mary Caraker; Ronald Anthony Cross; Kit Reed; Harry Turtledove; Isaac Asimov Manufacturer: Mercury Press ProductGroup: Book Binding: Paperback ASIN: B000RLSGTY |
Books:
Recommended Books